Diabetic nephropathy.
作者信息
Wylie Emma C, Satchell Simon C
机构信息
Richard Bright Renal Unit, Southmead Hospital, Bristol.
出版信息
Clin Med (Lond). 2012 Oct;12(5):480-2; quiz 483-5. doi: 10.7861/clinmedicine.12-5-480.
Abstract
摘要
相似文献
1
Diabetic nephropathy.糖尿病肾病
Clin Med (Lond). 2012 Oct;12(5):480-2; quiz 483-5. doi: 10.7861/clinmedicine.12-5-480.
2
Diabetic nephropathy--where next?糖尿病肾病——何去何从？
QJM. 2000 Oct;93(10):643-6. doi: 10.1093/qjmed/93.10.643.
3
The role of angiotensin receptor blockers in diabetic nephropathy.血管紧张素受体阻滞剂在糖尿病肾病中的作用。
Postgrad Med. 2011 May;123(3):109-21. doi: 10.3810/pgm.2011.05.2289.
4
[Diabetic nephropathy. Are the blood pressure values set too low?].[糖尿病肾病。血压值设定得过低了吗？]
MMW Fortschr Med. 2003 Dec 4;145(49):14.
5
[Treatment recommendations for various stages in diabetic nephropathy].[糖尿病肾病各阶段的治疗建议]
Nihon Rinsho. 2005 Jun;63 Suppl 6:379-83.
6
Diabetic Kidney Disease.糖尿病肾病
Clin J Am Soc Nephrol. 2018 Feb 7;13(2):335-338. doi: 10.2215/CJN.04650417. Epub 2017 Oct 18.
7
Comment on: The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D?述评：血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂在糖尿病高血压和非高血压患者中的应用现状。维生素 D 是否有一席之地？
Saudi Med J. 2021 Jan;42(1):115. doi: 10.15537/smj.2021.1.25621.
8
Introduction.引言。
Acta Diabetol. 2005 Apr;42 Suppl 1:S1-2. doi: 10.1007/s00592-005-0174-2.
9
Management of diabetic nephropathy.糖尿病肾病的管理
J R Soc Med. 2001 May;94(5):210-7. doi: 10.1177/014107680109400504.
10
Diabetic nephropathy: early detection, prevention and management.糖尿病肾病：早期检测、预防与管理
Am Fam Physician. 1992 Apr;45(4):1661-8.
本文引用的文献
1
Reversal of diabetic nephropathy: lessons from pancreas transplantation.糖尿病肾病的逆转：胰腺移植的经验教训。
J Nephrol. 2012 Jan-Feb;25(1):13-8. doi: 10.5301/jn.5000061.
2
Renal Association Clinical Practice Guideline on the assessment of the potential kidney transplant recipient.肾脏协会关于潜在肾移植受者评估的临床实践指南。
Nephron Clin Pract. 2011;118 Suppl 1:c209-24. doi: 10.1159/000328070. Epub 2011 May 6.
3
Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus.识别、发病机制和治疗 2 型糖尿病患者不同阶段的肾病。
Mayo Clin Proc. 2011 May;86(5):444-56. doi: 10.4065/mcp.2010.0713.
4
Limitations and future treatment options in type 2 diabetes with renal impairment.2型糖尿病合并肾功能损害的局限性及未来治疗选择
Diabetes Care. 2011 May;34 Suppl 2(Suppl 2):S330-4. doi: 10.2337/dc11-s242.
5
Diabetic kidney disease with and without albuminuria.糖尿病肾病伴或不伴白蛋白尿。
Curr Opin Nephrol Hypertens. 2011 May;20(3):246-57. doi: 10.1097/MNH.0b013e3283456546.
6
Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.阿利吉仑与氯沙坦联合使用可降低 2 型糖尿病肾病患者的蛋白尿，而与基线血压无关。
Clin J Am Soc Nephrol. 2011 May;6(5):1025-31. doi: 10.2215/CJN.07590810. Epub 2011 Feb 24.
7
Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.胱抑素 C 作为 2 型糖尿病患者肾病的早期生物标志物。
J Korean Med Sci. 2011 Feb;26(2):258-63. doi: 10.3346/jkms.2011.26.2.258. Epub 2011 Jan 24.
8
Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation.阿司匹林用于糖尿病患者心血管事件的一级预防：美国糖尿病协会立场声明、美国心脏协会科学声明及美国心脏病学基金会专家共识文件
Circulation. 2010 Jun 22;121(24):2694-701. doi: 10.1161/CIR.0b013e3181e3b133. Epub 2010 May 27.
9
Effects of intensive blood-pressure control in type 2 diabetes mellitus.强化血压控制对 2 型糖尿病的影响。
N Engl J Med. 2010 Apr 29;362(17):1575-85. doi: 10.1056/NEJMoa1001286. Epub 2010 Mar 14.
10
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials.阿司匹林用于糖尿病患者心血管事件的一级预防：随机对照试验的荟萃分析
BMJ. 2009 Nov 6;339:b4531. doi: 10.1136/bmj.b4531.
Zotero 插件